185 related articles for article (PubMed ID: 16291017)
1. Pharmacogenomics of statin responsiveness.
Kajinami K; Akao H; Polisecki E; Schaefer EJ
Am J Cardiol; 2005 Nov; 96(9A):65K-70K; discussion 34K-35K. PubMed ID: 16291017
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics of cholesterol-lowering therapy.
Schmitz G; Langmann T
Vascul Pharmacol; 2006 Feb; 44(2):75-89. PubMed ID: 16337220
[TBL] [Abstract][Full Text] [Related]
3. Statin pharmacogenomics: what have we learned, and what remains unanswered?
Kajinami K; Okabayashi M; Sato R; Polisecki E; Schaefer EJ
Curr Opin Lipidol; 2005 Dec; 16(6):606-13. PubMed ID: 16276236
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics of statin response.
Mangravite LM; Wilke RA; Zhang J; Krauss RM
Curr Opin Mol Ther; 2008 Dec; 10(6):555-61. PubMed ID: 19051133
[TBL] [Abstract][Full Text] [Related]
5. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
6. [Statin pharmacokinetics].
Hubácek JA; Adámková V; Zídková K; Ceska R; Zlatohlávek L; Stulc T; Horínek A; Vrablík M
Vnitr Lek; 2008 Jan; 54(1):62-7. PubMed ID: 18390119
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy.
Schmitz G; Schmitz-Madry A; Ugocsai P
Curr Opin Lipidol; 2007 Apr; 18(2):164-73. PubMed ID: 17353665
[TBL] [Abstract][Full Text] [Related]
8. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with statins and omega-3 fatty acids.
Nambi V; Ballantyne CM
Am J Cardiol; 2006 Aug; 98(4A):34i-38i. PubMed ID: 16919515
[TBL] [Abstract][Full Text] [Related]
10. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.
Mason RP; Walter MF; Day CA; Jacob RF
Am J Cardiol; 2005 Sep; 96(5A):11F-23F. PubMed ID: 16126019
[TBL] [Abstract][Full Text] [Related]
11. Statins personalized.
Superko HR; Momary KM; Li Y
Med Clin North Am; 2012 Jan; 96(1):123-39. PubMed ID: 22391257
[TBL] [Abstract][Full Text] [Related]
12. Continuation of statin treatment and all-cause mortality: a population-based cohort study.
Shalev V; Chodick G; Silber H; Kokia E; Jan J; Heymann AD
Arch Intern Med; 2009 Feb; 169(3):260-8. PubMed ID: 19204217
[TBL] [Abstract][Full Text] [Related]
13. The genetic determinants of atorvastatin response.
Rodrigues AC; Hirata MH; Hirata RD
Curr Opin Mol Ther; 2007 Dec; 9(6):545-53. PubMed ID: 18041665
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomics of statin response.
Mangravite LM; Krauss RM
Curr Opin Lipidol; 2007 Aug; 18(4):409-14. PubMed ID: 17620857
[TBL] [Abstract][Full Text] [Related]
15. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?
Ray KK; Cannon CP; Ganz P
Am J Cardiol; 2006 Dec; 98(11A):18P-25P. PubMed ID: 17126675
[TBL] [Abstract][Full Text] [Related]
16. Variation in Niemann-Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men.
Chan DC; Watts GF; Wang J; Hegele RA; van Bockxmeer FM; Barrett PH
Clin Endocrinol (Oxf); 2008 Jul; 69(1):45-51. PubMed ID: 18031309
[TBL] [Abstract][Full Text] [Related]
17. Comparison of utilization of statin therapy at hospital discharge and six-month outcomes in patients with an acute coronary syndrome and serum low-density lipoprotein>or=100 mg/dl versus<100 mg/dl.
Spencer FA; Goldberg RJ; Gore JM; Fox KA; Avezum A; Agnelli G; Kritharides L; Anderson FA; Goodman SG; FitzGerald G; Allegrone J; Brieger D;
Am J Cardiol; 2007 Sep; 100(6):913-8. PubMed ID: 17826369
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of statins therapy.
Puccetti L; Acampa M; Auteri A
Recent Pat Cardiovasc Drug Discov; 2007 Nov; 2(3):228-36. PubMed ID: 18221122
[TBL] [Abstract][Full Text] [Related]
19. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
Daskalopoulou SS; Mikhailidis DP
Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
Sharma R; Mahajan M; Singh B; Bal BS; Kant R
J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
